Global and China Paediatric Vaccine research
Global and China Paediatric Vaccine research

Paediatric Vaccine Comprehensive Study by Type (Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis, MMR, PediatricHormones, HIB, AllergyandRespiratoryvaccines, OtherPediatricvaccines), Application (Infectious Disease, Allergies), Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Other), End-User (Hospitals, Pediatric Clinics, Research Organizations, Others), Age Group (Age(0-3), Age(3-12), AgeAbove12) Players and Region - Global Market Outlook to 2025

Paediatric Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 248 Pages 169 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Paediatric Vaccine Market Scope?
Vaccination is the mechanism used to strengthen the immune system in the fight against certain antigens. It involves the injection of antigens, which are weaker versions of target viruses. These antigens produce antibodies when the body is exposed to similar types of antigens in the future. This is one of the easiest ways to prepare your body to fight certain diseases. Most vaccines are given when the immune system is developing. Vaccines are made with components that will keep your baby safe and effective against the disease. Each vaccine contains a small number of germs (viruses or bacteria) or germs. Examples are pertussis viruses (whooping cough pneumonia), measles virus, and tetanus toxoid. These vaccines do not cause disease because the germs have either died or amplified and the toxoids are also dormant. Vaccines make it easier to protect your child's immune system from disease. Several kinds of therapies are being performed around the world so as to find a reliable treatment for Covid-19. One line of treatment hereby includes the use of hydroxychloroquine, while the second line of treatment greatly focuses on the usage of antiviral drugs, which are used in the treatment of HIV. Both approaches have increased the demand for advanced antivirals and anti-malarial drugs. This has an impact on drug manufacturers, as work has to be done on an off-label indication for these drug classes.

The Paediatric Vaccine market study is being classified by Type (Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis, MMR, PediatricHormones, HIB, AllergyandRespiratoryvaccines and OtherPediatricvaccines), by Application (Infectious Disease and Allergies) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Paediatric Vaccine market throughout the predicted period.

GlaxoSmithKline (United Kingdom), Merck & Co. (United States), Sanofi (France), Bristol-Myers Squibb (United States), Abbott Laboratories (United States), Eli Lilly and Company (United States), Pfizer (United States), F. Hoffmann-La Roche (Switzerland) and Novo Nordisk (Denmark) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Paediatric Vaccine market by Type, Application and Region.

On the basis of geography, the market of Paediatric Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


The FDA Modernization Act (FDAMA) of 1997 renewed PDUFA user fees and performance goals and provided additional funding to support drug premarket review activities. The FDAMA included measures to modernize the regulation of biological products by synchronizing their review process with that of drugs and eliminating the requirement for an establishment license for biologicals. Expedited approval mechanisms for life-threatening conditions were authorized as well as the use of surrogate endpoints in clinical trials. The FDAMA also included a pediatric exclusivity provision that granted 6 months of market exclusivity to sponsors who conduct pediatric studies on the active ingredients of their drugs at the request of the FDA.

Influencing Market Trend
  • Increasing Awareness Regarding Vaccines and Immunization among the Populace
  • Increasing Development of Multivalent Vaccines

Market Drivers
  • Significance and Awareness of Security against the Burden of Chronic Diseases Is Propelling the Growth of the Market
  • High Prevalence of Chronic Diseases Is Driving the Growth of the Market

Opportunities
  • Technological Advances in Vaccines Is Boosting the Growth of the Market
  • Boost in Government and Non-Government R&D Funding Is Contributing To the Growth of the Market

Restraints
  • Cost of Immunization Is Very High Is Hampering the Growth of the Market
  • Limited Healthcare and High Reliability Is Hindering the Growth of the Market

Challenges
  • The Difficulties Connected With the Growth, Transport, and Management of Vaccines Is Hampering the Growth of the Market


Key Target Audience
Manufacturers of Paediatric Vaccine, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory, End-Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Pneumococcal
  • Varicella
  • Combinations
  • Poliovirus
  • Hepatitis
  • MMR
  • PediatricHormones
  • HIB
  • AllergyandRespiratoryvaccines
  • OtherPediatricvaccines
By Application
  • Infectious Disease
  • Allergies
By Technology
  • Live Attenuated
  • Inactivated
  • Subunit
  • Toxoid
  • Conjugate
  • Other

By End-User
  • Hospitals
  • Pediatric Clinics
  • Research Organizations
  • Others

By Age Group
  • Age(0-3)
  • Age(3-12)
  • AgeAbove12

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Significance and Awareness of Security against the Burden of Chronic Diseases Is Propelling the Growth of the Market
      • 3.2.2. High Prevalence of Chronic Diseases Is Driving the Growth of the Market
    • 3.3. Market Challenges
      • 3.3.1. The Difficulties Connected With the Growth, Transport, and Management of Vaccines Is Hampering the Growth of the Market
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness Regarding Vaccines and Immunization among the Populace
      • 3.4.2. Increasing Development of Multivalent Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Paediatric Vaccine, by Type, Application, Technology, End-User, Age Group and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Paediatric Vaccine (Value)
      • 5.2.1. Global Paediatric Vaccine by: Type (Value)
        • 5.2.1.1. Pneumococcal
        • 5.2.1.2. Varicella
        • 5.2.1.3. Combinations
        • 5.2.1.4. Poliovirus
        • 5.2.1.5. Hepatitis
        • 5.2.1.6. MMR
        • 5.2.1.7. PediatricHormones
        • 5.2.1.8. HIB
        • 5.2.1.9. AllergyandRespiratoryvaccines
        • 5.2.1.10. OtherPediatricvaccines
      • 5.2.2. Global Paediatric Vaccine by: Application (Value)
        • 5.2.2.1. Infectious Disease
        • 5.2.2.2. Allergies
      • 5.2.3. Global Paediatric Vaccine by: Technology (Value)
        • 5.2.3.1. Live Attenuated
        • 5.2.3.2. Inactivated
        • 5.2.3.3. Subunit
        • 5.2.3.4. Toxoid
        • 5.2.3.5. Conjugate
        • 5.2.3.6. Other
      • 5.2.4. Global Paediatric Vaccine by: End-User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Pediatric Clinics
        • 5.2.4.3. Research Organizations
        • 5.2.4.4. Others
      • 5.2.5. Global Paediatric Vaccine by: Age Group (Value)
        • 5.2.5.1. Age(0-3)
        • 5.2.5.2. Age(3-12)
        • 5.2.5.3. AgeAbove12
      • 5.2.6. Global Paediatric Vaccine Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Paediatric Vaccine (Volume)
      • 5.3.1. Global Paediatric Vaccine by: Type (Volume)
        • 5.3.1.1. Pneumococcal
        • 5.3.1.2. Varicella
        • 5.3.1.3. Combinations
        • 5.3.1.4. Poliovirus
        • 5.3.1.5. Hepatitis
        • 5.3.1.6. MMR
        • 5.3.1.7. PediatricHormones
        • 5.3.1.8. HIB
        • 5.3.1.9. AllergyandRespiratoryvaccines
        • 5.3.1.10. OtherPediatricvaccines
      • 5.3.2. Global Paediatric Vaccine by: Application (Volume)
        • 5.3.2.1. Infectious Disease
        • 5.3.2.2. Allergies
      • 5.3.3. Global Paediatric Vaccine by: Technology (Volume)
        • 5.3.3.1. Live Attenuated
        • 5.3.3.2. Inactivated
        • 5.3.3.3. Subunit
        • 5.3.3.4. Toxoid
        • 5.3.3.5. Conjugate
        • 5.3.3.6. Other
      • 5.3.4. Global Paediatric Vaccine by: End-User (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Pediatric Clinics
        • 5.3.4.3. Research Organizations
        • 5.3.4.4. Others
      • 5.3.5. Global Paediatric Vaccine by: Age Group (Volume)
        • 5.3.5.1. Age(0-3)
        • 5.3.5.2. Age(3-12)
        • 5.3.5.3. AgeAbove12
      • 5.3.6. Global Paediatric Vaccine Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Paediatric Vaccine (Price)
      • 5.4.1. Global Paediatric Vaccine by: Type (Price)
  • 6. Paediatric Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novo Nordisk (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Paediatric Vaccine Sale, by Type, Application, Technology, End-User, Age Group and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Paediatric Vaccine (Value)
      • 7.2.1. Global Paediatric Vaccine by: Type (Value)
        • 7.2.1.1. Pneumococcal
        • 7.2.1.2. Varicella
        • 7.2.1.3. Combinations
        • 7.2.1.4. Poliovirus
        • 7.2.1.5. Hepatitis
        • 7.2.1.6. MMR
        • 7.2.1.7. PediatricHormones
        • 7.2.1.8. HIB
        • 7.2.1.9. AllergyandRespiratoryvaccines
        • 7.2.1.10. OtherPediatricvaccines
      • 7.2.2. Global Paediatric Vaccine by: Application (Value)
        • 7.2.2.1. Infectious Disease
        • 7.2.2.2. Allergies
      • 7.2.3. Global Paediatric Vaccine by: Technology (Value)
        • 7.2.3.1. Live Attenuated
        • 7.2.3.2. Inactivated
        • 7.2.3.3. Subunit
        • 7.2.3.4. Toxoid
        • 7.2.3.5. Conjugate
        • 7.2.3.6. Other
      • 7.2.4. Global Paediatric Vaccine by: End-User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Pediatric Clinics
        • 7.2.4.3. Research Organizations
        • 7.2.4.4. Others
      • 7.2.5. Global Paediatric Vaccine by: Age Group (Value)
        • 7.2.5.1. Age(0-3)
        • 7.2.5.2. Age(3-12)
        • 7.2.5.3. AgeAbove12
      • 7.2.6. Global Paediatric Vaccine Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Paediatric Vaccine (Volume)
      • 7.3.1. Global Paediatric Vaccine by: Type (Volume)
        • 7.3.1.1. Pneumococcal
        • 7.3.1.2. Varicella
        • 7.3.1.3. Combinations
        • 7.3.1.4. Poliovirus
        • 7.3.1.5. Hepatitis
        • 7.3.1.6. MMR
        • 7.3.1.7. PediatricHormones
        • 7.3.1.8. HIB
        • 7.3.1.9. AllergyandRespiratoryvaccines
        • 7.3.1.10. OtherPediatricvaccines
      • 7.3.2. Global Paediatric Vaccine by: Application (Volume)
        • 7.3.2.1. Infectious Disease
        • 7.3.2.2. Allergies
      • 7.3.3. Global Paediatric Vaccine by: Technology (Volume)
        • 7.3.3.1. Live Attenuated
        • 7.3.3.2. Inactivated
        • 7.3.3.3. Subunit
        • 7.3.3.4. Toxoid
        • 7.3.3.5. Conjugate
        • 7.3.3.6. Other
      • 7.3.4. Global Paediatric Vaccine by: End-User (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Pediatric Clinics
        • 7.3.4.3. Research Organizations
        • 7.3.4.4. Others
      • 7.3.5. Global Paediatric Vaccine by: Age Group (Volume)
        • 7.3.5.1. Age(0-3)
        • 7.3.5.2. Age(3-12)
        • 7.3.5.3. AgeAbove12
      • 7.3.6. Global Paediatric Vaccine Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Paediatric Vaccine (Price)
      • 7.4.1. Global Paediatric Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Paediatric Vaccine: by Type(USD Million)
  • Table 2. Paediatric Vaccine Pneumococcal , by Region USD Million (2014-2019)
  • Table 3. Paediatric Vaccine Varicella , by Region USD Million (2014-2019)
  • Table 4. Paediatric Vaccine Combinations , by Region USD Million (2014-2019)
  • Table 5. Paediatric Vaccine Poliovirus , by Region USD Million (2014-2019)
  • Table 6. Paediatric Vaccine Hepatitis , by Region USD Million (2014-2019)
  • Table 7. Paediatric Vaccine MMR , by Region USD Million (2014-2019)
  • Table 8. Paediatric Vaccine PediatricHormones , by Region USD Million (2014-2019)
  • Table 9. Paediatric Vaccine HIB , by Region USD Million (2014-2019)
  • Table 10. Paediatric Vaccine AllergyandRespiratoryvaccines , by Region USD Million (2014-2019)
  • Table 11. Paediatric Vaccine OtherPediatricvaccines , by Region USD Million (2014-2019)
  • Table 12. Paediatric Vaccine: by Application(USD Million)
  • Table 13. Paediatric Vaccine Infectious Disease , by Region USD Million (2014-2019)
  • Table 14. Paediatric Vaccine Allergies , by Region USD Million (2014-2019)
  • Table 15. Paediatric Vaccine: by Technology(USD Million)
  • Table 16. Paediatric Vaccine Live Attenuated , by Region USD Million (2014-2019)
  • Table 17. Paediatric Vaccine Inactivated , by Region USD Million (2014-2019)
  • Table 18. Paediatric Vaccine Subunit , by Region USD Million (2014-2019)
  • Table 19. Paediatric Vaccine Toxoid , by Region USD Million (2014-2019)
  • Table 20. Paediatric Vaccine Conjugate , by Region USD Million (2014-2019)
  • Table 21. Paediatric Vaccine Other , by Region USD Million (2014-2019)
  • Table 22. Paediatric Vaccine: by End-User(USD Million)
  • Table 23. Paediatric Vaccine Hospitals , by Region USD Million (2014-2019)
  • Table 24. Paediatric Vaccine Pediatric Clinics , by Region USD Million (2014-2019)
  • Table 25. Paediatric Vaccine Research Organizations , by Region USD Million (2014-2019)
  • Table 26. Paediatric Vaccine Others , by Region USD Million (2014-2019)
  • Table 27. Paediatric Vaccine: by Age Group(USD Million)
  • Table 28. Paediatric Vaccine Age(0-3) , by Region USD Million (2014-2019)
  • Table 29. Paediatric Vaccine Age(3-12) , by Region USD Million (2014-2019)
  • Table 30. Paediatric Vaccine AgeAbove12 , by Region USD Million (2014-2019)
  • Table 31. South America Paediatric Vaccine, by Country USD Million (2014-2019)
  • Table 32. South America Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 33. South America Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 34. South America Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 35. South America Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 36. South America Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 37. Brazil Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 38. Brazil Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 39. Brazil Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 40. Brazil Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 41. Brazil Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 42. Argentina Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 43. Argentina Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 44. Argentina Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 45. Argentina Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 46. Argentina Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 47. Rest of South America Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 48. Rest of South America Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 49. Rest of South America Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 50. Rest of South America Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 51. Rest of South America Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 52. Asia Pacific Paediatric Vaccine, by Country USD Million (2014-2019)
  • Table 53. Asia Pacific Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 54. Asia Pacific Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 55. Asia Pacific Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 56. Asia Pacific Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 57. Asia Pacific Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 58. China Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 59. China Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 60. China Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 61. China Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 62. China Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 63. Japan Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 64. Japan Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 65. Japan Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 66. Japan Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 67. Japan Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 68. India Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 69. India Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 70. India Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 71. India Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 72. India Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 73. South Korea Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 74. South Korea Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 75. South Korea Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 76. South Korea Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 77. South Korea Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 78. Taiwan Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 79. Taiwan Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 80. Taiwan Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 81. Taiwan Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 82. Taiwan Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 83. Australia Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 84. Australia Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 85. Australia Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 86. Australia Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 87. Australia Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 88. Rest of Asia-Pacific Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 89. Rest of Asia-Pacific Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 90. Rest of Asia-Pacific Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 91. Rest of Asia-Pacific Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 92. Rest of Asia-Pacific Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 93. Europe Paediatric Vaccine, by Country USD Million (2014-2019)
  • Table 94. Europe Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 95. Europe Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 96. Europe Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 97. Europe Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 98. Europe Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 99. Germany Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 100. Germany Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 101. Germany Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 102. Germany Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 103. Germany Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 104. France Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 105. France Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 106. France Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 107. France Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 108. France Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 109. Italy Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 110. Italy Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 111. Italy Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 112. Italy Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 113. Italy Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 114. United Kingdom Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 115. United Kingdom Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 116. United Kingdom Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 117. United Kingdom Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 118. United Kingdom Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 119. Netherlands Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 120. Netherlands Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 121. Netherlands Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 122. Netherlands Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 123. Netherlands Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 124. Rest of Europe Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 125. Rest of Europe Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 126. Rest of Europe Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 127. Rest of Europe Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 128. Rest of Europe Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 129. MEA Paediatric Vaccine, by Country USD Million (2014-2019)
  • Table 130. MEA Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 131. MEA Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 132. MEA Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 133. MEA Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 134. MEA Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 135. Middle East Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 136. Middle East Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 137. Middle East Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 138. Middle East Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 139. Middle East Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 140. Africa Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 141. Africa Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 142. Africa Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 143. Africa Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 144. Africa Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 145. North America Paediatric Vaccine, by Country USD Million (2014-2019)
  • Table 146. North America Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 147. North America Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 148. North America Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 149. North America Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 150. North America Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 151. United States Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 152. United States Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 153. United States Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 154. United States Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 155. United States Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 156. Canada Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 157. Canada Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 158. Canada Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 159. Canada Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 160. Canada Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 161. Mexico Paediatric Vaccine, by Type USD Million (2014-2019)
  • Table 162. Mexico Paediatric Vaccine, by Application USD Million (2014-2019)
  • Table 163. Mexico Paediatric Vaccine, by Technology USD Million (2014-2019)
  • Table 164. Mexico Paediatric Vaccine, by End-User USD Million (2014-2019)
  • Table 165. Mexico Paediatric Vaccine, by Age Group USD Million (2014-2019)
  • Table 166. Paediatric Vaccine Sales: by Type(K Tons)
  • Table 167. Paediatric Vaccine Sales Pneumococcal , by Region K Tons (2014-2019)
  • Table 168. Paediatric Vaccine Sales Varicella , by Region K Tons (2014-2019)
  • Table 169. Paediatric Vaccine Sales Combinations , by Region K Tons (2014-2019)
  • Table 170. Paediatric Vaccine Sales Poliovirus , by Region K Tons (2014-2019)
  • Table 171. Paediatric Vaccine Sales Hepatitis , by Region K Tons (2014-2019)
  • Table 172. Paediatric Vaccine Sales MMR , by Region K Tons (2014-2019)
  • Table 173. Paediatric Vaccine Sales PediatricHormones , by Region K Tons (2014-2019)
  • Table 174. Paediatric Vaccine Sales HIB , by Region K Tons (2014-2019)
  • Table 175. Paediatric Vaccine Sales AllergyandRespiratoryvaccines , by Region K Tons (2014-2019)
  • Table 176. Paediatric Vaccine Sales OtherPediatricvaccines , by Region K Tons (2014-2019)
  • Table 177. Paediatric Vaccine Sales: by Application(K Tons)
  • Table 178. Paediatric Vaccine Sales Infectious Disease , by Region K Tons (2014-2019)
  • Table 179. Paediatric Vaccine Sales Allergies , by Region K Tons (2014-2019)
  • Table 180. Paediatric Vaccine Sales: by Technology(K Tons)
  • Table 181. Paediatric Vaccine Sales Live Attenuated , by Region K Tons (2014-2019)
  • Table 182. Paediatric Vaccine Sales Inactivated , by Region K Tons (2014-2019)
  • Table 183. Paediatric Vaccine Sales Subunit , by Region K Tons (2014-2019)
  • Table 184. Paediatric Vaccine Sales Toxoid , by Region K Tons (2014-2019)
  • Table 185. Paediatric Vaccine Sales Conjugate , by Region K Tons (2014-2019)
  • Table 186. Paediatric Vaccine Sales Other , by Region K Tons (2014-2019)
  • Table 187. Paediatric Vaccine Sales: by End-User(K Tons)
  • Table 188. Paediatric Vaccine Sales Hospitals , by Region K Tons (2014-2019)
  • Table 189. Paediatric Vaccine Sales Pediatric Clinics , by Region K Tons (2014-2019)
  • Table 190. Paediatric Vaccine Sales Research Organizations , by Region K Tons (2014-2019)
  • Table 191. Paediatric Vaccine Sales Others , by Region K Tons (2014-2019)
  • Table 192. Paediatric Vaccine Sales: by Age Group(K Tons)
  • Table 193. Paediatric Vaccine Sales Age(0-3) , by Region K Tons (2014-2019)
  • Table 194. Paediatric Vaccine Sales Age(3-12) , by Region K Tons (2014-2019)
  • Table 195. Paediatric Vaccine Sales AgeAbove12 , by Region K Tons (2014-2019)
  • Table 196. South America Paediatric Vaccine Sales, by Country K Tons (2014-2019)
  • Table 197. South America Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 198. South America Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 199. South America Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 200. South America Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 201. South America Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 202. Brazil Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 203. Brazil Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 204. Brazil Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 205. Brazil Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 206. Brazil Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 207. Argentina Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 208. Argentina Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 209. Argentina Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 210. Argentina Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 211. Argentina Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 212. Rest of South America Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 213. Rest of South America Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 214. Rest of South America Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 215. Rest of South America Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 216. Rest of South America Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 217. Asia Pacific Paediatric Vaccine Sales, by Country K Tons (2014-2019)
  • Table 218. Asia Pacific Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 219. Asia Pacific Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 220. Asia Pacific Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 221. Asia Pacific Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 222. Asia Pacific Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 223. China Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 224. China Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 225. China Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 226. China Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 227. China Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 228. Japan Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 229. Japan Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 230. Japan Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 231. Japan Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 232. Japan Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 233. India Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 234. India Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 235. India Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 236. India Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 237. India Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 238. South Korea Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 239. South Korea Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 240. South Korea Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 241. South Korea Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 242. South Korea Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 243. Taiwan Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 244. Taiwan Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 245. Taiwan Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 246. Taiwan Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 247. Taiwan Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 248. Australia Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 249. Australia Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 250. Australia Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 251. Australia Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 252. Australia Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 253. Rest of Asia-Pacific Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 254. Rest of Asia-Pacific Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 255. Rest of Asia-Pacific Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 256. Rest of Asia-Pacific Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 257. Rest of Asia-Pacific Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 258. Europe Paediatric Vaccine Sales, by Country K Tons (2014-2019)
  • Table 259. Europe Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 260. Europe Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 261. Europe Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 262. Europe Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 263. Europe Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 264. Germany Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 265. Germany Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 266. Germany Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 267. Germany Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 268. Germany Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 269. France Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 270. France Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 271. France Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 272. France Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 273. France Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 274. Italy Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 275. Italy Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 276. Italy Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 277. Italy Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 278. Italy Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 279. United Kingdom Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 280. United Kingdom Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 281. United Kingdom Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 282. United Kingdom Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 283. United Kingdom Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 284. Netherlands Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 285. Netherlands Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 286. Netherlands Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 287. Netherlands Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 288. Netherlands Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 289. Rest of Europe Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 290. Rest of Europe Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 291. Rest of Europe Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 292. Rest of Europe Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 293. Rest of Europe Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 294. MEA Paediatric Vaccine Sales, by Country K Tons (2014-2019)
  • Table 295. MEA Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 296. MEA Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 297. MEA Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 298. MEA Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 299. MEA Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 300. Middle East Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 301. Middle East Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 302. Middle East Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 303. Middle East Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 304. Middle East Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 305. Africa Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 306. Africa Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 307. Africa Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 308. Africa Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 309. Africa Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 310. North America Paediatric Vaccine Sales, by Country K Tons (2014-2019)
  • Table 311. North America Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 312. North America Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 313. North America Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 314. North America Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 315. North America Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 316. United States Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 317. United States Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 318. United States Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 319. United States Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 320. United States Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 321. Canada Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 322. Canada Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 323. Canada Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 324. Canada Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 325. Canada Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 326. Mexico Paediatric Vaccine Sales, by Type K Tons (2014-2019)
  • Table 327. Mexico Paediatric Vaccine Sales, by Application K Tons (2014-2019)
  • Table 328. Mexico Paediatric Vaccine Sales, by Technology K Tons (2014-2019)
  • Table 329. Mexico Paediatric Vaccine Sales, by End-User K Tons (2014-2019)
  • Table 330. Mexico Paediatric Vaccine Sales, by Age Group K Tons (2014-2019)
  • Table 331. Paediatric Vaccine: by Type(USD/Units)
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Company Basic Information, Sales Area and Its Competitors
  • Table 339. Company Basic Information, Sales Area and Its Competitors
  • Table 340. Company Basic Information, Sales Area and Its Competitors
  • Table 341. Paediatric Vaccine: by Type(USD Million)
  • Table 342. Paediatric Vaccine Pneumococcal , by Region USD Million (2020-2025)
  • Table 343. Paediatric Vaccine Varicella , by Region USD Million (2020-2025)
  • Table 344. Paediatric Vaccine Combinations , by Region USD Million (2020-2025)
  • Table 345. Paediatric Vaccine Poliovirus , by Region USD Million (2020-2025)
  • Table 346. Paediatric Vaccine Hepatitis , by Region USD Million (2020-2025)
  • Table 347. Paediatric Vaccine MMR , by Region USD Million (2020-2025)
  • Table 348. Paediatric Vaccine PediatricHormones , by Region USD Million (2020-2025)
  • Table 349. Paediatric Vaccine HIB , by Region USD Million (2020-2025)
  • Table 350. Paediatric Vaccine AllergyandRespiratoryvaccines , by Region USD Million (2020-2025)
  • Table 351. Paediatric Vaccine OtherPediatricvaccines , by Region USD Million (2020-2025)
  • Table 352. Paediatric Vaccine: by Application(USD Million)
  • Table 353. Paediatric Vaccine Infectious Disease , by Region USD Million (2020-2025)
  • Table 354. Paediatric Vaccine Allergies , by Region USD Million (2020-2025)
  • Table 355. Paediatric Vaccine: by Technology(USD Million)
  • Table 356. Paediatric Vaccine Live Attenuated , by Region USD Million (2020-2025)
  • Table 357. Paediatric Vaccine Inactivated , by Region USD Million (2020-2025)
  • Table 358. Paediatric Vaccine Subunit , by Region USD Million (2020-2025)
  • Table 359. Paediatric Vaccine Toxoid , by Region USD Million (2020-2025)
  • Table 360. Paediatric Vaccine Conjugate , by Region USD Million (2020-2025)
  • Table 361. Paediatric Vaccine Other , by Region USD Million (2020-2025)
  • Table 362. Paediatric Vaccine: by End-User(USD Million)
  • Table 363. Paediatric Vaccine Hospitals , by Region USD Million (2020-2025)
  • Table 364. Paediatric Vaccine Pediatric Clinics , by Region USD Million (2020-2025)
  • Table 365. Paediatric Vaccine Research Organizations , by Region USD Million (2020-2025)
  • Table 366. Paediatric Vaccine Others , by Region USD Million (2020-2025)
  • Table 367. Paediatric Vaccine: by Age Group(USD Million)
  • Table 368. Paediatric Vaccine Age(0-3) , by Region USD Million (2020-2025)
  • Table 369. Paediatric Vaccine Age(3-12) , by Region USD Million (2020-2025)
  • Table 370. Paediatric Vaccine AgeAbove12 , by Region USD Million (2020-2025)
  • Table 371. South America Paediatric Vaccine, by Country USD Million (2020-2025)
  • Table 372. South America Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 373. South America Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 374. South America Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 375. South America Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 376. South America Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 377. Brazil Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 378. Brazil Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 379. Brazil Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 380. Brazil Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 381. Brazil Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 382. Argentina Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 383. Argentina Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 384. Argentina Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 385. Argentina Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 386. Argentina Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 387. Rest of South America Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 388. Rest of South America Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 389. Rest of South America Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 390. Rest of South America Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 391. Rest of South America Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 392. Asia Pacific Paediatric Vaccine, by Country USD Million (2020-2025)
  • Table 393. Asia Pacific Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 394. Asia Pacific Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 395. Asia Pacific Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 396. Asia Pacific Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 397. Asia Pacific Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 398. China Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 399. China Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 400. China Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 401. China Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 402. China Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 403. Japan Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 404. Japan Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 405. Japan Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 406. Japan Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 407. Japan Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 408. India Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 409. India Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 410. India Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 411. India Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 412. India Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 413. South Korea Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 414. South Korea Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 415. South Korea Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 416. South Korea Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 417. South Korea Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 418. Taiwan Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 419. Taiwan Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 420. Taiwan Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 421. Taiwan Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 422. Taiwan Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 423. Australia Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 424. Australia Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 425. Australia Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 426. Australia Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 427. Australia Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 428. Rest of Asia-Pacific Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 429. Rest of Asia-Pacific Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 430. Rest of Asia-Pacific Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 431. Rest of Asia-Pacific Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 432. Rest of Asia-Pacific Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 433. Europe Paediatric Vaccine, by Country USD Million (2020-2025)
  • Table 434. Europe Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 435. Europe Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 436. Europe Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 437. Europe Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 438. Europe Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 439. Germany Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 440. Germany Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 441. Germany Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 442. Germany Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 443. Germany Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 444. France Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 445. France Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 446. France Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 447. France Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 448. France Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 449. Italy Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 450. Italy Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 451. Italy Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 452. Italy Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 453. Italy Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 454. United Kingdom Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 455. United Kingdom Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 456. United Kingdom Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 457. United Kingdom Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 458. United Kingdom Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 459. Netherlands Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 460. Netherlands Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 461. Netherlands Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 462. Netherlands Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 463. Netherlands Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 464. Rest of Europe Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 465. Rest of Europe Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 466. Rest of Europe Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 467. Rest of Europe Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 468. Rest of Europe Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 469. MEA Paediatric Vaccine, by Country USD Million (2020-2025)
  • Table 470. MEA Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 471. MEA Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 472. MEA Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 473. MEA Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 474. MEA Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 475. Middle East Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 476. Middle East Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 477. Middle East Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 478. Middle East Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 479. Middle East Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 480. Africa Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 481. Africa Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 482. Africa Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 483. Africa Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 484. Africa Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 485. North America Paediatric Vaccine, by Country USD Million (2020-2025)
  • Table 486. North America Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 487. North America Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 488. North America Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 489. North America Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 490. North America Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 491. United States Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 492. United States Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 493. United States Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 494. United States Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 495. United States Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 496. Canada Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 497. Canada Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 498. Canada Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 499. Canada Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 500. Canada Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 501. Mexico Paediatric Vaccine, by Type USD Million (2020-2025)
  • Table 502. Mexico Paediatric Vaccine, by Application USD Million (2020-2025)
  • Table 503. Mexico Paediatric Vaccine, by Technology USD Million (2020-2025)
  • Table 504. Mexico Paediatric Vaccine, by End-User USD Million (2020-2025)
  • Table 505. Mexico Paediatric Vaccine, by Age Group USD Million (2020-2025)
  • Table 506. Paediatric Vaccine Sales: by Type(K Tons)
  • Table 507. Paediatric Vaccine Sales Pneumococcal , by Region K Tons (2020-2025)
  • Table 508. Paediatric Vaccine Sales Varicella , by Region K Tons (2020-2025)
  • Table 509. Paediatric Vaccine Sales Combinations , by Region K Tons (2020-2025)
  • Table 510. Paediatric Vaccine Sales Poliovirus , by Region K Tons (2020-2025)
  • Table 511. Paediatric Vaccine Sales Hepatitis , by Region K Tons (2020-2025)
  • Table 512. Paediatric Vaccine Sales MMR , by Region K Tons (2020-2025)
  • Table 513. Paediatric Vaccine Sales PediatricHormones , by Region K Tons (2020-2025)
  • Table 514. Paediatric Vaccine Sales HIB , by Region K Tons (2020-2025)
  • Table 515. Paediatric Vaccine Sales AllergyandRespiratoryvaccines , by Region K Tons (2020-2025)
  • Table 516. Paediatric Vaccine Sales OtherPediatricvaccines , by Region K Tons (2020-2025)
  • Table 517. Paediatric Vaccine Sales: by Application(K Tons)
  • Table 518. Paediatric Vaccine Sales Infectious Disease , by Region K Tons (2020-2025)
  • Table 519. Paediatric Vaccine Sales Allergies , by Region K Tons (2020-2025)
  • Table 520. Paediatric Vaccine Sales: by Technology(K Tons)
  • Table 521. Paediatric Vaccine Sales Live Attenuated , by Region K Tons (2020-2025)
  • Table 522. Paediatric Vaccine Sales Inactivated , by Region K Tons (2020-2025)
  • Table 523. Paediatric Vaccine Sales Subunit , by Region K Tons (2020-2025)
  • Table 524. Paediatric Vaccine Sales Toxoid , by Region K Tons (2020-2025)
  • Table 525. Paediatric Vaccine Sales Conjugate , by Region K Tons (2020-2025)
  • Table 526. Paediatric Vaccine Sales Other , by Region K Tons (2020-2025)
  • Table 527. Paediatric Vaccine Sales: by End-User(K Tons)
  • Table 528. Paediatric Vaccine Sales Hospitals , by Region K Tons (2020-2025)
  • Table 529. Paediatric Vaccine Sales Pediatric Clinics , by Region K Tons (2020-2025)
  • Table 530. Paediatric Vaccine Sales Research Organizations , by Region K Tons (2020-2025)
  • Table 531. Paediatric Vaccine Sales Others , by Region K Tons (2020-2025)
  • Table 532. Paediatric Vaccine Sales: by Age Group(K Tons)
  • Table 533. Paediatric Vaccine Sales Age(0-3) , by Region K Tons (2020-2025)
  • Table 534. Paediatric Vaccine Sales Age(3-12) , by Region K Tons (2020-2025)
  • Table 535. Paediatric Vaccine Sales AgeAbove12 , by Region K Tons (2020-2025)
  • Table 536. South America Paediatric Vaccine Sales, by Country K Tons (2020-2025)
  • Table 537. South America Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 538. South America Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 539. South America Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 540. South America Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 541. South America Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 542. Brazil Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 543. Brazil Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 544. Brazil Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 545. Brazil Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 546. Brazil Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 547. Argentina Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 548. Argentina Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 549. Argentina Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 550. Argentina Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 551. Argentina Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 552. Rest of South America Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 553. Rest of South America Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 554. Rest of South America Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 555. Rest of South America Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 556. Rest of South America Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 557. Asia Pacific Paediatric Vaccine Sales, by Country K Tons (2020-2025)
  • Table 558. Asia Pacific Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 559. Asia Pacific Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 560. Asia Pacific Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 561. Asia Pacific Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 562. Asia Pacific Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 563. China Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 564. China Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 565. China Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 566. China Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 567. China Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 568. Japan Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 569. Japan Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 570. Japan Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 571. Japan Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 572. Japan Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 573. India Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 574. India Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 575. India Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 576. India Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 577. India Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 578. South Korea Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 579. South Korea Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 580. South Korea Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 581. South Korea Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 582. South Korea Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 583. Taiwan Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 584. Taiwan Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 585. Taiwan Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 586. Taiwan Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 587. Taiwan Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 588. Australia Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 589. Australia Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 590. Australia Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 591. Australia Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 592. Australia Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 593. Rest of Asia-Pacific Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 594. Rest of Asia-Pacific Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 595. Rest of Asia-Pacific Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 596. Rest of Asia-Pacific Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 597. Rest of Asia-Pacific Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 598. Europe Paediatric Vaccine Sales, by Country K Tons (2020-2025)
  • Table 599. Europe Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 600. Europe Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 601. Europe Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 602. Europe Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 603. Europe Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 604. Germany Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 605. Germany Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 606. Germany Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 607. Germany Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 608. Germany Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 609. France Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 610. France Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 611. France Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 612. France Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 613. France Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 614. Italy Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 615. Italy Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 616. Italy Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 617. Italy Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 618. Italy Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 619. United Kingdom Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 620. United Kingdom Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 621. United Kingdom Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 622. United Kingdom Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 623. United Kingdom Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 624. Netherlands Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 625. Netherlands Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 626. Netherlands Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 627. Netherlands Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 628. Netherlands Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 629. Rest of Europe Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 630. Rest of Europe Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 631. Rest of Europe Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 632. Rest of Europe Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 633. Rest of Europe Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 634. MEA Paediatric Vaccine Sales, by Country K Tons (2020-2025)
  • Table 635. MEA Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 636. MEA Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 637. MEA Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 638. MEA Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 639. MEA Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 640. Middle East Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 641. Middle East Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 642. Middle East Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 643. Middle East Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 644. Middle East Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 645. Africa Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 646. Africa Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 647. Africa Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 648. Africa Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 649. Africa Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 650. North America Paediatric Vaccine Sales, by Country K Tons (2020-2025)
  • Table 651. North America Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 652. North America Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 653. North America Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 654. North America Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 655. North America Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 656. United States Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 657. United States Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 658. United States Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 659. United States Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 660. United States Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 661. Canada Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 662. Canada Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 663. Canada Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 664. Canada Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 665. Canada Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 666. Mexico Paediatric Vaccine Sales, by Type K Tons (2020-2025)
  • Table 667. Mexico Paediatric Vaccine Sales, by Application K Tons (2020-2025)
  • Table 668. Mexico Paediatric Vaccine Sales, by Technology K Tons (2020-2025)
  • Table 669. Mexico Paediatric Vaccine Sales, by End-User K Tons (2020-2025)
  • Table 670. Mexico Paediatric Vaccine Sales, by Age Group K Tons (2020-2025)
  • Table 671. Paediatric Vaccine: by Type(USD/Units)
  • Table 672. Research Programs/Design for This Report
  • Table 673. Key Data Information from Secondary Sources
  • Table 674. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Paediatric Vaccine: by Type USD Million (2014-2019)
  • Figure 5. Global Paediatric Vaccine: by Application USD Million (2014-2019)
  • Figure 6. Global Paediatric Vaccine: by Technology USD Million (2014-2019)
  • Figure 7. Global Paediatric Vaccine: by End-User USD Million (2014-2019)
  • Figure 8. Global Paediatric Vaccine: by Age Group USD Million (2014-2019)
  • Figure 9. South America Paediatric Vaccine Share (%), by Country
  • Figure 10. Asia Pacific Paediatric Vaccine Share (%), by Country
  • Figure 11. Europe Paediatric Vaccine Share (%), by Country
  • Figure 12. MEA Paediatric Vaccine Share (%), by Country
  • Figure 13. North America Paediatric Vaccine Share (%), by Country
  • Figure 14. Global Paediatric Vaccine: by Type K Tons (2014-2019)
  • Figure 15. Global Paediatric Vaccine: by Application K Tons (2014-2019)
  • Figure 16. Global Paediatric Vaccine: by Technology K Tons (2014-2019)
  • Figure 17. Global Paediatric Vaccine: by End-User K Tons (2014-2019)
  • Figure 18. Global Paediatric Vaccine: by Age Group K Tons (2014-2019)
  • Figure 19. South America Paediatric Vaccine Share (%), by Country
  • Figure 20. Asia Pacific Paediatric Vaccine Share (%), by Country
  • Figure 21. Europe Paediatric Vaccine Share (%), by Country
  • Figure 22. MEA Paediatric Vaccine Share (%), by Country
  • Figure 23. North America Paediatric Vaccine Share (%), by Country
  • Figure 24. Global Paediatric Vaccine: by Type USD/Units (2014-2019)
  • Figure 25. Global Paediatric Vaccine share by Players 2019 (%)
  • Figure 26. Global Paediatric Vaccine share by Players (Top 3) 2019(%)
  • Figure 27. Global Paediatric Vaccine share by Players (Top 5) 2019(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 31. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co. (United States) Revenue: by Geography 2019
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2019
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2019
  • Figure 37. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 38. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 39. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 41. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer (United States) Revenue: by Geography 2019
  • Figure 43. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2019
  • Figure 45. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 46. Novo Nordisk (Denmark) Revenue: by Geography 2019
  • Figure 47. Global Paediatric Vaccine: by Type USD Million (2020-2025)
  • Figure 48. Global Paediatric Vaccine: by Application USD Million (2020-2025)
  • Figure 49. Global Paediatric Vaccine: by Technology USD Million (2020-2025)
  • Figure 50. Global Paediatric Vaccine: by End-User USD Million (2020-2025)
  • Figure 51. Global Paediatric Vaccine: by Age Group USD Million (2020-2025)
  • Figure 52. South America Paediatric Vaccine Share (%), by Country
  • Figure 53. Asia Pacific Paediatric Vaccine Share (%), by Country
  • Figure 54. Europe Paediatric Vaccine Share (%), by Country
  • Figure 55. MEA Paediatric Vaccine Share (%), by Country
  • Figure 56. North America Paediatric Vaccine Share (%), by Country
  • Figure 57. Global Paediatric Vaccine: by Type K Tons (2020-2025)
  • Figure 58. Global Paediatric Vaccine: by Application K Tons (2020-2025)
  • Figure 59. Global Paediatric Vaccine: by Technology K Tons (2020-2025)
  • Figure 60. Global Paediatric Vaccine: by End-User K Tons (2020-2025)
  • Figure 61. Global Paediatric Vaccine: by Age Group K Tons (2020-2025)
  • Figure 62. South America Paediatric Vaccine Share (%), by Country
  • Figure 63. Asia Pacific Paediatric Vaccine Share (%), by Country
  • Figure 64. Europe Paediatric Vaccine Share (%), by Country
  • Figure 65. MEA Paediatric Vaccine Share (%), by Country
  • Figure 66. North America Paediatric Vaccine Share (%), by Country
  • Figure 67. Global Paediatric Vaccine: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. (United States)
  • Sanofi (France)
  • Bristol-Myers Squibb (United States)
  • Abbott Laboratories (United States)
  • Eli Lilly and Company (United States)
  • Pfizer (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Novo Nordisk (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation